FEATURED AUTHORITIES ON DIABETES MANAGAMENT
iQ&A interactive Medical Intelligence Zone welcomes your questions and your participation in the iQ&A community.
Course Videos
How do you think you will use the combination formulations in real practice? How will you titrate these agents?
What aspects of GLP-1 RA do you think are most important for the practicing physician caring for patients with T2D?
What degree of HA1c lowering are studies reporting with fixed ratio combinations using a basal insulin plus GLP-1 RA?
What degree of HA1c lowering do the studies report with the use of GLP-1 RAs?
What degree of HA1c lowering do the studies report with the use of GLP-1 RAs?
At what point in the ADA and AACE sequencing algorithm for glycemic control in patients with T2D is the use of GLP-1 RA recommended? What are the treatment triggers for GLP-1 RA?
What is the mechanism by which GLP-1 RAs induce weight loss?
What is the mechanism by which GLP-1 RAs induce weight loss?
Does the LEADER trial data provide any guidance for how we might use fixed ratio combinations of basal insulin plus GLP-1 RA, or should we avoid such cross-trial comparisons?
Can we extrapolate from what we learned about liraglutide in the LEADER trial to combination therapy that would employ a basal insulin in combination with this GLP-1 RA?
What is meant exactly by a "fixed ratio" combination?
What is meant exactly by a “fixed ratio” combination?
What should we expect as far as weight gain, risk of hypoglycemia, and degree of HA1c lowering with fixed ratio combinations such a iGlarLixi and iDegLira?
How important is the mechanistic complementarity between basal insulin and GLP-1 RAs and what implication does this have for the safety and efficacy of fixed ratio combinations such as iGlarLixi and iDegLira?
What have your studies shown as far as the optimal way to advance basal insulin therapy, and combining basal insulin with either prandial insulin or a GLP-1 RA?